Lupin gets DCGI approval for IVABRAD drug

Mumbai, Nov 10 (UNI) Pharmaceutical major Lupin has received approval from the Drugs Controller General of India (DCGI) for its new IF channel inhibitor-''IVABRAD(Ivabradine)'' drug for Coronary Artery Disease(CAD) patients.

According to a company statement made today, the drug already available in the market, is the country's first in the Rs 3,663.8 crore cardiac related drug market will be used in treatment of symptomatic chronic stable angina disease in CAD patients.

IVABARD lowers the heart rate by 22 per cent.

''Statistics today, suggest an alarming rise in lifestyle diseases in the next few years, and treatments such as IVABRAD will go a long way towards controlling these diseases,''said Lupin India Region Formulations President Shakti P Chakraborty.

The the company's speciality drug marketing arm Pinnacle is handling the drug which comes in in five mg and 7.5 mg tablets.

According to the World Health Organization (WHO), mortality due to cardiac ailments in India which has the highest mortality and morbidity rates from heart attacks in the world will increase by 100 per cent by 2015.

UNI ZC ZA NP1441